Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
Delivered Q1 2026 Total Revenues of $149.4 Million Results include 28% YoY Increase in Net Product Revenues from FIRDAPSE® & AGAMREE® Reported Cash and Cash Equivalents of $755.9 Million...
Barchart Research What to Expect from CPRX Earnings CPRX Generated May 8, 2026 Current Price $31.15 EPS Estimate $$0.58 Consensus Rating Strong Buy Average Move 5.18% CPRX's Rare Disease Portfolio May...
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Catalyst Pharmaceuticals...
Barchart Research What to Expect from CPRX Earnings CPRX Generated May 8, 2026 Current Price $31.15 EPS Estimate $$0.58 Consensus Rating Strong Buy Average Move 5.18% CPRX's Rare Disease Portfolio May...
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
Barchart Research What to Expect from CPRX Earnings CPRX Generated May 8, 2026 Current Price $31.15 EPS Estimate $$0.58 Consensus Rating Strong Buy Average Move 5.18% CPRX's Rare Disease Portfolio May...
CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...
MILWAUKEE , May 7, 2026 /PRNewswire/ -- Ademi LLP is investigating Catalyst (NASDAQ: CPRX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction...